Tamtam Try Tamtam free
Globus Medical logo

Globus Medical account plan

advanced orthopedic surgical products

At a glance

Globus Medical makes spine, trauma and joint implants, spinal cord stimulators and surgical robots: FY2025 net sales $2,938.9 million, over 6,000 employees.

Globus Medical, Inc., founded in 2003 and headquartered in Audubon, Pennsylvania, is a musculoskeletal medical device company. It sells spine, orthopedic trauma, hip and knee implants, biologics, intraoperative neuromonitoring, spinal cord stimulation (through Nevro, acquired April 3, 2025) and the Excelsius imaging, navigation and robotics systems, mainly to hospitals, ambulatory surgery centers and surgeons in the U.S. and 64 countries outside it. FY2025 net sales were $2,938.9 million (up 16.7%), operating income $479.8 million and net income $537.9 million. It had over 6,000 employees at December 31, 2025. It is an NYSE controlled company: Executive Chairman David C. Paul and family hold about 66.1% of voting power.

Business units

Strategic priorities

Product launches in spine
SCRIPT patient-specific implants and rods, the XLIF prone lateral solution and the EIQ pedicle fixation suite with AI planning are expected to be "meaningful contributors to revenue in 2027 and beyond"; well over 60 projects are in development.
Competitive sales rep recruiting
Grow the exclusive U.S. sales force; Q2 2026 hires were double those of Q1, and recruiting remains central to the growth strategy.
Surgical intelligence ecosystem
Combine implants, enabling technology, procedural solutions and AI-based surgeon intelligence; Higgs-Boson was acquired to build a "surgical intelligence layer".
Margin recovery
Adjusted gross margin of 69% to 70% expected for 2026 with a return to the mid-70s targeted; adjusted EBITDA margin was 34.3% in Q3 2026.
Stabilise Nevro
Rehire Nevro sales staff and recover trial volumes; HFX Elite, the first new IPG since the acquisition, is slated for the first half of 2027.
2027 growth ambition
Not guidance: the CEO's goal is "growing mid to high single digits top line" with earnings outgrowing revenue, while R&D spending steps up.

Latest results

Q3 2026 net sales were $763.7 million, down 0.7% from $769.0 million; the base business excluding Nevro was $690 million, up 3%, while Nevro fell 25.7% to $73.7 million. U.S. sales were $621.0 million (+0.5%) and international $142.7 million (-5.7%). Net income rose to $141.2 million and diluted EPS to $1.04, helped by manufacturing cost cuts and a lower litigation provision. For the nine months, net sales were $2,313.2 million (+9.5%). 2026 revenue guidance was cut to $3.09 billion from $3.18-$3.22 billion, while non-GAAP EPS guidance of $4.95-$5.05 was reiterated.

Investments and deals

Nevro acquisition
Acquired April 3, 2025 for $5.85 per share in cash; it contributed $293.6 million of revenue in 2025 and a $117.7 million bargain purchase gain.
Tuck-in acquisitions
Higgs-Boson (digital and AI surgical intelligence) and the Synaptive assets (entry into cranial neurosurgery, about 2 million procedures a year) closed in Q3 2026.
Share buybacks
3.5 million shares repurchased for $279.0 million in the first nine months of 2026; on November 2, 2026 the board added $500.0 million, leaving about $611.0 million available.
Surgical sets and capacity
Capital priorities put internal product development first, then surgical sets and manufacturing capacity, then buybacks, then M&A.

Challenges and risks

Spine execution
The CEO blamed "timing delays with new product introductions and lingering production issues" and lower contributions from competitive recruiting for U.S. Spine growth of 1.8% in Q3 2026.
Nevro decline
Spinal cord stimulation sales fell $22.1 million in the U.S. in Q3 2026 on lower trial volumes; Nevro revenue fell 25.7%.
Capital model transition
The shift to rental, lease and volume-based robot placements lowers upfront Enabling Technologies revenue; capital sales cycles are long and variable.
Pricing, reimbursement and competition
Procedures move to outpatient settings with lower reimbursement, payors require prior authorisation, and Medtronic, DePuy Synthes, Stryker, Zimmer Biomet and Smith + Nephew compete.
Litigation
A $43.1 million liability was recorded for the Pimenta case against NuVasive, and a 4WEB patent suit concerns Modulus products.

What leadership says

“I think there's things that we could have done better to achieve the growth that we thought we were going to get.”

Keith Pfeil, President and CEO · Q3 2026 earnings call, November 5, 2026

“since 2022, Globus has more than tripled our top line and earnings”

Keith Pfeil, President and CEO · Q2 2026 earnings call, August 6, 2026

“Our strategy doesn't move from quarter to quarter”

Keith Pfeil, President and CEO · Q3 2026 earnings call, November 5, 2026

Where a supplier can help

Manufacturing and supply reliability
Tied to the spine execution challenge: suppliers and production partners that ease lingering production issues and support launches such as SCRIPT 3D-printed cages fit the launch plan.
Sales force recruiting and enablement
Tied to the competitive recruiting priority: recruiting, onboarding and sales productivity tools support the exclusive U.S. sales force.
AI and surgical data
Tied to the surgical intelligence ecosystem priority: data platforms, AI planning software and cloud infrastructure fit the Higgs-Boson and EIQ work.
Capital placement financing
Tied to the capital model transition: leasing, financing and asset-tracking services could support rental and volume-based robot placements.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Globus Medical?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Globus Medical

What does Globus Medical do?

Globus Medical makes spine, orthopedic trauma, hip and knee implants, biologics, neuromonitoring services, Nevro spinal cord stimulators and the Excelsius robotic and navigation systems used by surgeons.

What is Globus Medical's revenue?

FY2025 net sales were $2,938.9 million, up 16.7%; 2026 revenue guidance is $3.09 billion.

How many employees does Globus Medical have?

Over 6,000 employees worldwide at December 31, 2025.

Who leads Globus Medical?

Keith W. Pfeil is President and CEO, Kyle R. Kline is CFO and David C. Paul is Executive Chairman.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)